文献速递中毒与环境急症重症综合管理与镇静镇痛

美国国家中毒数据系统中有意鲁拉西酮摄入的特征分析

Characterization of intentional lurasidone ingestions using the United States National Poison Data System.
PubMed 文献 · Clin Toxicol (Phila) · 2020-03-13
一句话结论鲁拉西酮有意过量多数临床过程良好,重大效应少见(0.7%),无死亡,但重症监护入住率较高且近半数未接受关键治疗。

该研究回顾分析2011至2018年美国国家中毒数据系统(NPDS)中1753例单药有意鲁拉西酮过量病例,平均年龄28.6岁(SD=13.3岁),68.4%为女性,86.6%编码为疑似自杀。最终处置中65.2%出院或转入精神科机构,18.8%住院,住院者中半数入住重症监护病房(CCU)。重大效应仅12例(0.7%),中度效应259例(14.8%),轻度效应531例(30%),无效应614例(35%),无死亡。在有剂量信息的病例中,按临床效应分析中位剂量无统计学显著差异。最常见不良反应为嗜睡(25.6%)、心动过速(14.5%)、呕吐(6.9%)和高血压(6.6%)。入住CCU的164例中80例(48.8%)仅接受无治疗或单纯静脉补液。作者认为鲁拉西酮有意过量重大效应不常见,尽管CCU入住率高,但相当比例未接受关键治疗。

要点

  • 1753例单药有意鲁拉西酮过量中,重大效应仅12例(0.7%),无死亡,总体临床过程良好。
  • 最常见不良反应为嗜睡(449例,25.6%)、心动过速(254例,14.5%)、呕吐(121例,6.9%)、高血压(115例,6.6%)。
  • 18.8%(328例)住院,住院者中半数入住CCU;入住CCU的164例中80例(48.8%)仅接受无治疗或单纯静脉补液。
  • 有剂量信息的病例中,按临床效应分析中位剂量无统计学显著差异。
  • 57.6%(1010例)无治疗报告或毒物中心建议治疗但确认未执行。

适用人群与场景

  • 2011至2018年美国国家中毒数据系统(NPDS)中单药有意鲁拉西酮摄入的成人和儿童病例,平均年龄28.6岁(SD=13.3岁),68.4%为女性。

研究设计与关键结果

  • 研究类型为回顾性分析,样本量1753例单药有意鲁拉西酮过量,数据来自美国国家中毒数据系统(NPDS)2011至2018年。
  • 平均年龄28.6岁(SD=13.3岁),1199例(68.4%)为女性,86.6%编码为疑似自杀。
  • 最终处置:1143例(65.2%)出院或转入精神科机构;328例(18.8%)住院,其中半数入住重症监护病房(CCU)。
  • 临床效应:重大效应12例(0.7%),中度效应259例(14.8%),轻度效应531例(30%),无效应614例(35%),无死亡。
  • 有剂量信息的病例中,按临床效应分析中位剂量无统计学显著差异。
  • 最常见不良反应:嗜睡449例(25.6%),心动过速254例(14.5%),呕吐121例(6.9%),高血压115例(6.6%)。
  • 治疗情况:1010例(57.6%)无治疗报告或毒物中心建议治疗但确认未执行;入住CCU的164例中80例(48.8%)仅接受无治疗或单纯静脉补液。

证据类型、等级与局限

  • 证据类型:基于美国国家中毒数据系统(NPDS)的回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为鲁拉西酮有意过量重大效应不常见,临床过程通常良好;尽管CCU入住率高,但相当比例未接受关键治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Introduction: The ziprasidone analogue lurasidone is approved for the treatment of schizophrenia and bipolar disorder for adults and children older than 10 years. Small studies and case reports suggest lurasidone overdose is not generally associated with major adverse effects, but no large sample has been published.Objective: To describe intentional lurasidone overdoses reported to poison centers.Methods: Retrospective analysis of single-substance intentional lurasidone ingestions from the National Poison Data System (NPDS) from 2011 to 2018.Results: There were 1753 single-substance intentional overdoses. Average age was 28.6 years (SD = 13.3 years) and 1199 (68.4%) of patients were female. Most cases (86.6%) were coded as suspected suicide. Regarding final management site, 1143 (65.2%) were discharged or admitted to psychiatric facilities; 328 (18.8%) were admitted, half of whom were admitted to critical care units (CCUs). Major effect was coded in 12 (0.7%), moderate effect in 259 (14.8%), minor effect in 531 (30%), and no effect in 614 (35%). There were no deaths. For cases for which dose information was available, there was not a statistically significant difference between median doses when analyzed by clinical effect. Most common adverse effects were drowsiness (449, 25.6%), tachycardia (254, 14.5%), vomiting (121, 6.9%), and hypertension (115, 6.6%). Most cases had either no therapy reported, or therapy was recommended by the poison center but confirmed not to have been administered (1010, 57.6%). Of the 164 patients admitted to CCUs, 80 (48.8%) received either no therapy or intravenous fluids alone.Discussion: These data suggest major effects are uncommon from lurasidone overdose. Despite a high rate of admission to CCUs, a substantial proportion received no critical therapies.Conclusions: This report demonstrates intentional lurasidone overdoses reported to poison centers generally have a favorable clinical course.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Weiss SJ, Cueto-Vilorio VA, Dharmaraj R, et al. Characterization of intentional lurasidone ingestions using the United States National Poison Data System. Clin Toxicol (Phila). 2020. PMID: 32167797. doi:10.1080/15563650.2020.1737102

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。